It's nice to see the PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS) share price up 21% in a week. But that doesn't change the fact that the returns over the last year have been less than pleasing. In fact, the price has declined 45% in a year, falling short of the returns you could get by investing in an index fund.

While the stock has risen 21% in the past week but long term shareholders are still in the red, let's see what the fundamentals can tell us.

View our latest analysis for PhaseBio Pharmaceuticals

PhaseBio Pharmaceuticals isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. When a company doesn't make profits, we'd generally expect to see good revenue growth. That's because it's hard to be confident a company will be sustainable if revenue growth is negligible, and it never makes a profit.

In the last year PhaseBio Pharmaceuticals saw its revenue grow by 885%. That's well above most other pre-profit companies. Given the revenue growth, the share price drop of 45% seems quite harsh. Our sympathies to shareholders who are now underwater. Prima facie, revenue growth like that should be a good thing, so it's worth checking whether losses have stabilized. Our brains have evolved to think in linear fashion, so there's value in learning to recognize exponential growth. We are, in some ways, simply the wisest of the monkeys.

You can see below how earnings and revenue have changed over time (discover the exact values by clicking on the image).

This free interactive report on PhaseBio Pharmaceuticals' balance sheet strength is a great place to start, if you want to investigate the stock further.

A Different Perspective

Over the last year, PhaseBio Pharmaceuticals shareholders took a loss of 45%. In contrast the market gained about 23%. Of course the long term matters more than the short term, and even great stocks will sometimes have a poor year. The three-year loss of 13% per year isn't as bad as the last twelve months, suggesting that the company has not been able to convince the market it has solved its problems. Although Baron Rothschild famously said to "buy when there's blood in the streets, even if the blood is your own", he also focusses on high quality stocks with solid prospects. It's always interesting to track share price performance over the longer term. But to understand PhaseBio Pharmaceuticals better, we need to consider many other factors. For instance, we've identified 5 warning signs for PhaseBio Pharmaceuticals (3 are a bit concerning) that you should be aware of.